SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/14/2796259/0/en/SELLAS-Life-Sciences-Announces-First-Patients-Enrolled-in-60-mg-Dose-Cohort-in-Phase-2a-Clinical-Trial-of-SLS009-in-Acute-Myeloid-Leukemia.html

– Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg –

– Patients in 60 mg Dose Cohort Will be Dosed with 60 mg Once per Week or 30 mg Twice per Week –

Read more at globenewswire.com

Related news for (SLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.